Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020709 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
NCT00020709: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00020709 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 840 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020709, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
Study Summary
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of tumors. It is not yet known whether combination chemotherapy plus radiation therapy is more effective with or without gefitinib in treating non-small cell lung cancer
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG etoposide
- RADIATION radiation therapy
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2001-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020709
The ClinicalTrials.gov registry entry for NCT00020709 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00020709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020709 about?
NCT00020709 is a clinical study titled "Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery". Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or ...
What is the current status of trial NCT00020709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2001-06.
What interventions are being tested in trial NCT00020709?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), etoposide (DRUG), radiation therapy (RADIATION), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00020709?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.